Literature DB >> 11020228

Kinetics of recovery from opioids at wild-type and mutant mu opioid receptors expressed in xenopus oocytes.

C E Spivak1, C L Beglan.   

Abstract

To investigate a previous observation that classical antagonists behave as agonists at mutant H297N and H297Q mu opioid receptors, we compared the kinetics of recovery from opioids at wild-type and mutant mu receptors expressed in voltage-clamped Xenopus oocytes. The cDNA for the potassium channel GIRK1 was coinjected into the oocytes with that of the mu receptors to transduce agonist binding into a coupled electrophysiological response. The kinetics of recovery were estimated by brief test pulses of the agonist normorphine given at a frequency of 0.67 or 1 per min. After treatment with a variety of agonists, the receptors recovered from desensitization at rates that depended on the agonist, but there was little difference between mutant and wild-type receptors. Antagonists, however, induced agonist-like currents and demonstrated faster recovery at the mutant receptors. These results suggest that His-297 may comprise part of an antagonist subsite. This conclusion, when coupled with the steric theory that intrinsic activity depends on independent binary equilibration of a drug between agonist and antagonist subsites, could unify the paired observations that antagonists become agonists and recover faster at the mutant than at the wild-type receptors. Synapse 38:254-260, 2000. Published 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11020228     DOI: 10.1002/1098-2396(20001201)38:3<254::AID-SYN4>3.0.CO;2-9

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  1 in total

1.  Enhanced GABAergic synaptic transmission at VLPAG neurons and potent modulation by oxycodone in a bone cancer pain model.

Authors:  Keiko Takasu; Koichi Ogawa; Atsushi Nakamura; Tomoe Kanbara; Hiroko Ono; Takako Tomii; Yasuhide Morioka; Minoru Hasegawa; Masahiro Shibasaki; Tomohisa Mori; Tsutomu Suzuki; Gaku Sakaguchi
Journal:  Br J Pharmacol       Date:  2015-02-10       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.